---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000015"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-04-05T23:59:59+00:00"
generated_at: "2026-06-17T05:50:23.718467+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AbbVie lowers 2023 adjusted EPS guidance by $0.08 on $150M Q1 IPR&D expense

## Summary
- Q1 2023 acquired IPR&D and milestones expense of $150M pre-tax reduces GAAP and adjusted EPS by $0.08.
- Q1 2023 adjusted diluted EPS guidance lowered to $2.31-$2.41 from $2.39-$2.49.
- Full-year 2023 adjusted diluted EPS guidance lowered to $10.62-$11.02 from $10.70-$11.10.
- Company does not forecast future IPR&D and milestones expense; guidance excludes any beyond Q1.

## SEC filing metadata
- accession: 0001551152-23-000015
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-04-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000015/0001551152-23-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000015/abbv-20230405.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000015
- JSON: https://secwatch.observer/filing/0001551152-23-000015.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.